PROCEPT BioRobotics Corporation
PRCTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. At a $1.14B market cap, PROCEPT BioRobotics Corporation ranks as a small-cap company within healthcare. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Market Cap
$1.14B
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-17.03
EPS (TTM)
$-1.94
EPS (Fwd)
$-1.17
ROE
-30.2%
ROA
-14.8%
Cash
$227.9M
Total Debt
$77.5M
Free CF
-$49.0M
52W Change
-43.0%
Annual Financials
Cash vs Debt
Where PRCT stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, PRCT finished 13.37% below its 150-day moving average ($22.59) and 19.30% below its 200-day moving average ($24.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRCT overbought or oversold?
At the October 13, 2026 close, PRCT's RSI(14) was 58.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $227.9M in cash and $77.5M in debt, PRCT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$49.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -30.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $75.0M (2022) to $308.1M (2025), reflecting a 311% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PROCEPT BioRobotics Corporation's trajectory.